Posted by Michael Wonder on 16 Feb 2018
Quebec and New Brunswick become first provinces to provide public funding of Ibrance for the first-line treatment of metastatic breast cancer
15 February 2018 - Since Ibrance received Health Canada marketing authorisation in March 2016, Canadian women living with metastatic breast cancer have waited close to two years for public access.
Pfizer Canada announces that Quebec and New Brunswick have become the first provinces in Canada to provide public funding of Ibrance (palbociclib) in combination with a non-steroidal aromatase inhibitor for the first-line treatment of postmenopausal women living with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (mBC).
Ibrance was added to Quebec's drug benefit formulary effective 1 February 2018 and New Brunswick's drug plan formulary effective 12 February 2018.
